Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

56
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
56
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

57
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
57
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

916
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
916

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isoprenoid pathway dysfunction in chronic fatigue syndrome.

Acta neuropsychiatrica·2016
Same author

Hypothalamic digoxin, hemispheric chemical dominance and sarcoidosis.

Acta neuropsychiatrica·2016
Same author

A cholesterol and actinide dependent shadow biosphere of archaea and viroids in autoimmune diseases.

Immunobiology·2011
Same author

Familial hypothalamic digoxin deficiency syndrome.

The Journal of neuropsychiatry and clinical neurosciences·2004
Same author

Hypothalamic digoxin-mediated model for trisomy 21.

Pediatric pathology & molecular medicine·2003
Same author

The isoprenoid pathway and the pathogenesis of Reye's syndrome.

Pediatric pathology & molecular medicine·2003
Same journal

Serum Levels of IFN-Îł and NGF as Potential Biomarkers of Depressive Disorders.

Acta neuropsychiatrica·2026
Same journal

The Danish Region Midt Schizophrenia Cohort - Representative, long-term follow-up of first-episode schizophrenia spectrum disorder.

Acta neuropsychiatrica·2026
Same journal

The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.

Acta neuropsychiatrica·2026
Same journal

Breaking down the ADHD construct to build a valid diagnosis.

Acta neuropsychiatrica·2026
Same journal

A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer's disease and dementia.

Acta neuropsychiatrica·2026
Same journal

Age-dependent increase in peripheral neuropeptide Y with no cross-sectional link to depression.

Acta neuropsychiatrica·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

3.0K

Hypothalamic digoxin-mediated model for epileptogenesis.

Ravi Kumar Kurup1, Parameswara Achutha Kurup2

  • 11Department of Medicine, Medical College Hospital, Trivandrum.

Acta Neuropsychiatrica
|March 18, 2016
PubMed
Summary
This summary is machine-generated.

Epilepsy may stem from a malfunctioning isoprenoid pathway, leading to altered metabolites and red blood cell membrane changes. This study investigates these metabolic disruptions in seizure disorders.

More Related Videos

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.7K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

3.3K

Related Experiment Videos

Last Updated: Mar 24, 2026

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

3.0K
A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.7K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

3.3K

Area of Science:

  • Biochemistry
  • Neuroscience
  • Metabolomics

Background:

  • Epilepsy is a neurological disorder characterized by recurrent seizures.
  • The isoprenoid pathway plays a crucial role in various cellular functions.
  • Dysregulation of this pathway may contribute to epileptogenesis.

Purpose of the Study:

  • To investigate alterations in the isoprenoid pathway and its metabolites in patients with seizure disorders.
  • To explore the metabolic cascade resulting from isoprenoid pathway dysregulation.
  • To examine changes in red blood cell membrane composition.

Main Methods:

  • Assessed isoprenoid pathway metabolites.
  • Analyzed tyrosine and tryptophan catabolites.
  • Evaluated glycoconjugates metabolism and red blood cell (RBC) membrane composition.

Main Results:

  • Elevated plasma HMG-CoA reductase activity, serum digoxin, and dolichol.
  • Reduced RBC membrane Na-K+ ATPase activity, serum magnesium, and ubiquinone.
  • Significant alterations in serum and RBC membrane metabolites, including lipids, amino acids, and glycosaminoglycans.

Conclusions:

  • A dysfunctional isoprenoid pathway may underlie epileptogenesis.
  • Paroxysmal hypothalamic digoxin hypersecretion is a potential contributing factor.
  • Metabolic dysregulation offers novel insights into epilepsy pathophysiology.